Table 1. Included patients fulfil a selected criteria in visual acuity (LogMAR), first-treated eye, visual acuity ≥0.7, and fellow eye visual acuity ≤0.3.

All patients	Age (years)	Females	Baseline VA	Most recent VA	Follow-up days	Subgroup patients	Baseline VA	Most recent VA
With selected visual criteria						Where worse-seeing eye -> better-seeing eye
Unilateral-treated 319 patients	78	58%			855	Unilateral-treated 20 patients
First eye			0.85 (42.3) (CL: 0.89–0.85)	0.59 (55.7) (CL: 0.64–0.54)		First eye	0.82 (43.8)	0.19 (75.3)
Fellow eye			0.14 (78.2) (CL: 0.15–0.12)	0.13 (78.5) (CL: 0.15–0.11)		Fellow eye	0.19 (75.3)	0.43 (63.4)
Bilateral-treated 152 patients	80	76%			1144	Bilateral-treated 20 patients
First eye			0.89 (40.7) (CL: 0.92–0.85)	0.80 (45.2) (CL: 0.89–0.74)		First eye	0.80 (45.2)	0.43 (63.4)
Second eye			0.17a (76.6) (CL: 0.18–0.15)	0.37 (66.7) (CL: 0.43–0.31)		Second eye	0.20a (75.0)	0.96 (37.1)

Abbreviations: CL, confidence limit; ETDRS, Early Treatment Diabetic Retinopathy Study.

Mean values, 95% CL.

Number of ETDRS letters in parenthesis next to visual acuity (LogMAR).

Note that visual gains are limited in this cohort compared with other cohorts as it is a select group with a long follow-up time.

^aBaseline VA for second eyes was assessed before diagnosis of nAMD in second-treated eye.